Skip to main content
. 2022 May 21;111:135–147. doi: 10.1016/j.reprotox.2022.05.012

Fig. 11.

Fig. 11

Impact of remdesivir and GS-441524 on the proliferation and viability of human embryonic stem cells. Graphs show the relative light unit of the CellTiter-Glo Luminescent Assay as a proxy for the relative number of metabolically active cells after 2 days of treatment. Different letters indicate statistically significant differences among treatments (mean ± standard deviation, n = 3 for each treatment group, one-way ANOVA followed by t-test, p < 0.01).